Edesa Biotech Stock Probability of Future Stock Price Finishing Under 2.37
| EDSA Stock | USD 2.44 0.07 2.95% |
Edesa |
Edesa Biotech Target Price Odds to finish below 2.37
The tendency of Edesa Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 2.37 or more in 90 days |
| 2.44 | 90 days | 2.37 | about 9.51 |
Based on a normal probability distribution, the odds of Edesa Biotech to drop to $ 2.37 or more in 90 days from now is about 9.51 (This Edesa Biotech probability density function shows the probability of Edesa Stock to fall within a particular range of prices over 90 days) . Probability of Edesa Biotech price to stay between $ 2.37 and its current price of $2.44 at the end of the 90-day period is about 1.37 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.33 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Edesa Biotech will likely underperform. Additionally Edesa Biotech has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Edesa Biotech Price Density |
| Price |
Predictive Modules for Edesa Biotech
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Edesa Biotech. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Edesa Biotech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Edesa Biotech Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Edesa Biotech is not an exception. The market had few large corrections towards the Edesa Biotech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Edesa Biotech, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Edesa Biotech within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.98 | |
β | Beta against Dow Jones | 1.33 | |
σ | Overall volatility | 0.91 | |
Ir | Information ratio | -0.23 |
Edesa Biotech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Edesa Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Edesa Biotech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Edesa Biotech generated a negative expected return over the last 90 days | |
| Edesa Biotech has high historical volatility and very poor performance | |
| Net Loss for the year was (8.37 M) with profit before overhead, payroll, taxes, and interest of 311.2 K. | |
| Edesa Biotech currently holds about 12.81 M in cash with (6.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.83. | |
| Edesa Biotech has a frail financial position based on the latest SEC disclosures | |
| Roughly 33.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Nijhawan Pardeep of 2765 shares of Edesa Biotech subject to Rule 16b-3 |
Edesa Biotech Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Edesa Stock often depends not only on the future outlook of the current and potential Edesa Biotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Edesa Biotech's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 2.9 M | |
| Cash And Short Term Investments | 5.4 M |
Edesa Biotech Technical Analysis
Edesa Biotech's future price can be derived by breaking down and analyzing its technical indicators over time. Edesa Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Edesa Biotech. In general, you should focus on analyzing Edesa Stock price patterns and their correlations with different microeconomic environments and drivers.
Edesa Biotech Predictive Forecast Models
Edesa Biotech's time-series forecasting models is one of many Edesa Biotech's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Edesa Biotech's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Edesa Biotech
Checking the ongoing alerts about Edesa Biotech for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Edesa Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Edesa Biotech generated a negative expected return over the last 90 days | |
| Edesa Biotech has high historical volatility and very poor performance | |
| Net Loss for the year was (8.37 M) with profit before overhead, payroll, taxes, and interest of 311.2 K. | |
| Edesa Biotech currently holds about 12.81 M in cash with (6.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.83. | |
| Edesa Biotech has a frail financial position based on the latest SEC disclosures | |
| Roughly 33.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Nijhawan Pardeep of 2765 shares of Edesa Biotech subject to Rule 16b-3 |
Check out Edesa Biotech Backtesting, Edesa Biotech Valuation, Edesa Biotech Correlation, Edesa Biotech Hype Analysis, Edesa Biotech Volatility, Edesa Biotech History as well as Edesa Biotech Performance. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.78) | Quarterly Revenue Growth (1.00) | Return On Assets (0.72) | Return On Equity (1.29) |
The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.